Search clinical trials for: PF-07321332

Total 1295 results

Pfizer

Active, not recruiting

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Non-small-cell Lung Cancer | Advanced Malignancies

China, Korea, Republic of, Taiwan, Japan, Russian Federation, Ukraine
Pfizer

Completed

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Ovarian Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States, Spain
Vicore Pharma AB
Curebase Inc.

Active, not recruiting

Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF (COMPANION)

Generalized Anxiety Disorder | Pulmonary Fibrosis

United States
Pfizer

Terminated

A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device

Healthy Volunteers

Belgium
Pfizer

Completed

Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

Reduction in Severity of Skin Scarring

United States
Stanford University

Withdrawn

PROMs To Improve Care- Standardized vs Patient Specific

Hand Injuries
Pfizer

Completed

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Healthy Volunteers

Belgium
Pfizer

Terminated

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

Huntington's Disease

United States, Germany, Poland, United Kingdom, Canada
Pfizer

Completed

A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Italy
Pfizer

Completed

A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377

Healthy

United States
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Alopecia Areata

United States, Canada, Australia
Quark Pharmaceuticals

Completed

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) (MATISSE)

Diabetic Retinopathy | Diabetic Macular Edema | Choroidal Neovascularization

United States, Israel, United Kingdom, Belgium, Germany, Poland, Czech Republic
Pfizer

Recruiting

A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.

COVID-19

United States
Biosense Webster, Inc.

Active, not recruiting

A Study For Treatment Of Paroxysmal Atrial Fibrillation (PAF) With The THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE Generator (SmartfIRE)

Atrial Fibrillation

Belgium, Denmark, Austria, Lithuania
Pfizer

Terminated

A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001)

Breast Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms

United States, Puerto Rico
Pfizer

Terminated

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Melanoma | Sarcoma | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Bladder Cancer | Renal Cell Cancer | Hepatocellular Cancer | Squamous Cell Carcinoma | Non-Small-Cell Lung Cancer

United States
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

Healthy Volunteers | Hepatic Impairment

United States
Pfizer

Active, not recruiting

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Japan
Pfizer

Completed

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Diabetic Nephropathies

United States, Korea, Republic of, Sweden, Canada, Hong Kong, Serbia, Denmark, Australia, Malaysia, Slovakia, South Africa, India, United Kingdom, Poland, Mexico
Catalyst Biosciences

Completed

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Hemophilia A

United States, Belgium, Hungary, Italy, New Zealand, South Africa, Turkey, United Kingdom
Pfizer
Bristol-Myers Squibb

Completed

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Healthy | Obesity | Overweight

United States
Pfizer

Completed

A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Canada, United Kingdom, Australia, Sweden
Pfizer

Completed

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

Diabetes Mellitus, Type 2

United States
Pfizer

Terminated

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Advanced Cancer

United States, Canada, United Kingdom, Taiwan, Australia, France, Japan, Poland
Bausch & Lomb Incorporated
NicOx Inc.

Completed

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Primary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative Glaucoma

United States
Fudan University

Completed

Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Cancer

China
Pfizer

Completed

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Healthy Subjects

United States
Pfizer

Recruiting

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

Shingles | Human | Herpes Zoster Infection

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Pfizer

Recruiting

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (MagnetisMM-20)

Multiple Myeloma

United States, Israel
Icahn School of Medicine at Mount Sinai
Pfizer

Recruiting

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

Seborrheic Dermatitis | Papulopustular Rosacea

United States
Pfizer

Completed

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

Liver Diseases | Hepatic Impairment

United States
Pfizer

Completed

2-Week Study In People With Nonalcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

United States
Pfizer

Completed

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Carcinoma, Non Small Cell Lung

United States
Pfizer

Completed

A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562

Healthy

United States
Pfizer
University of Wisconsin, Madison

Completed

A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors

Neoplasm

United States
Pfizer

Completed

A Study To Investigate The Elimination Of PF-06273588 From The Body Following A Single Low Dose.

Healthy Volunteers

United Kingdom
Pfizer
Yale University

Completed

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers (3193A1-1103)

Healthy

United States
Pfizer

Completed

Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects

Healthy Volunteers

Singapore
Biosense Webster, Inc.

Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS (PulseSmart)

Atrial Fibrillation

Australia, Canada
Pfizer

Active, not recruiting

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Multiple Myeloma

United States, Canada, Spain, Belgium, United Kingdom, Australia, Japan, France, Germany, Poland
Pfizer

Completed

A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin Amyloid Cardiomyopathy

China
Pfizer

Terminated

Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

Gout

United States
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population

Healthy

United States
Pfizer

Completed

Multiple Ascending Dose Study To Assess Safety, Tolerability And Pharmacokinetics Of PF-05212377 (SAM-760) (MAD)

Healthy

France
Pfizer

Terminated

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Healthy Subjects

Belgium
Pfizer

Completed

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Hungary, Taiwan, Romania, India, South Africa, Philippines, Slovakia
Pfizer

Recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Hemophilia A | Hemophilia B

Hong Kong, Spain, Serbia, Turkey, United States, China, Mexico, South Africa, India, Japan, Croatia, Korea, Republic of, Oman, Taiwan, Italy, Canada, France
Pfizer

Active, not recruiting

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Multiple Myeloma | Refractory Multiple Myeloma | Myeloma | Relapsed Multiple Myeloma | Elranatamab | PF-06863135 | BCMA | Bispecific | Bispecific Antibody | BCMA-CD3 Bispecific | MagnetisMM-8

China

3

Subscribe